ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 595,59
-0,49%
Dow Jones
40 211,72
0,53%
DAX
18 532,10
-0,37%
Brent Oil
83,665
-0,80%
Bitcoin
63 097,60
-2,70%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
13/06/201701h48Dow Jones NewsNassau County Sues Drugmakers Over Opioid EpidemicNYSE:TEVATeva Pharmaceutical Industries Ltd
12/06/201722h48Dow Jones NewsNassau County Sues Drug Makers Over Opioid EpidemicNYSE:TEVATeva Pharmaceutical Industries Ltd
12/06/201721h26Edgar (US Regulatory)Report of Foreign Issuer (6-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
12/06/201721h16Business WireTeva Announces Launch of Generic Zetia® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
09/06/201714h53Business WireTeva Announces Exclusive Launch of Generic Pataday® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
07/06/201714h00Business WireTeva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly & Quarterly Dosing Regimens in Phase III Stud...NYSE:TEVATeva Pharmaceutical Industries Ltd
06/06/201714h00Business WireTeva to Present at the Jefferies 2017 Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
01/06/201714h00Business WireTeva to Present Data from 18 Abstracts in Tardive Dyskinesia & Huntington Disease at the 21st International Congress of Parki...NYSE:TEVATeva Pharmaceutical Industries Ltd
01/06/201709h02Dow Jones NewsOpioid Makers Sued for Stoking Addiction -- WSJNYSE:TEVATeva Pharmaceutical Industries Ltd
01/06/201703h58Dow Jones NewsOhio Sues Five Drug Firms, Saying They Fueled Opioid Crisis -- 2nd UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
31/05/201723h16Edgar (US Regulatory)Specialized Disclosure Report (sd)NYSE:TEVATeva Pharmaceutical Industries Ltd
31/05/201721h12Dow Jones NewsOhio Sues Five Drug Firms, Saying They Fueled Opioid Crisis -- UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
31/05/201714h22Business WireTeva Announces Positive Results for Phase III Study of Fremanezumab for the Prevention of Chronic MigraineNYSE:TEVATeva Pharmaceutical Industries Ltd
17/05/201715h00Business WireTeva Showcases Asthma Research at the 2017 American Thoracic Society (ATS) International ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
17/05/201714h00Business WireTeva to Present Data for Deutetrabenazine in Tardive Dyskinesia at the American Psychiatric Association 2017 Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/201719h20Business WireTeva Announces Launch of Generic Glumetza® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/201714h00Business WireOtsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)NYSE:TEVATeva Pharmaceutical Industries Ltd
11/05/201713h00Business WireTeva Reports First Quarter 2017 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
09/05/201717h52Dow Jones NewsThin Is In as Allergan Dodges Generics Bullet -- Heard on the StreetNYSE:TEVATeva Pharmaceutical Industries Ltd
05/05/201720h00Business WireTeva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary EndpointNYSE:TEVATeva Pharmaceutical Industries Ltd
05/05/201714h00Business WireTeva Announces Publication of COPAXONE® (glatiramer acetate injection) Pregnancy Data in the International Journal of MS CareNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/201705h27Dow Jones NewsPerrigo Says Investigators Searched Its Offices in Generic-Drug ProbeNYSE:TEVATeva Pharmaceutical Industries Ltd
27/04/201714h00Business WireTeva Announces Publication of ARM-TD Study Results in Neurology® for the Investigational Use of Deutetrabenazine in Tardive ...NYSE:TEVATeva Pharmaceutical Industries Ltd
26/04/201722h09Business WireTeva Announces Launch of Generic Vytorin® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
26/04/201715h02Business WireTeva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial OfficerNYSE:TEVATeva Pharmaceutical Industries Ltd
20/04/201714h42Business WireTeva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and SalmeterolNYSE:TEVATeva Pharmaceutical Industries Ltd
19/04/201714h00Business WireTeva Showcases CNS Portfolio at 69th Annual Meeting of the American Academy of NeurologyNYSE:TEVATeva Pharmaceutical Industries Ltd
06/04/201714h30Business WireTeva to Report First Quarter 2017 Financial Results on May 11, 2017NYSE:TEVATeva Pharmaceutical Industries Ltd
03/04/201714h32Business WireTeva erzielt positives Ergebnis für Etikett von dreimal wöchentlichem COPAXONE® 40 mg/ml in EuropaNYSE:TEVATeva Pharmaceutical Industries Ltd
03/04/201713h08Business WireTeva obtient une issue positive pour l’étiquetage de COPAXONE® 40 mg/ml 3 fois par semaine en EuropeNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

EU
ML
Michelin
EU
CS
Axa
EU
AF
Air FranceKLM
EU
MC
Lvmh Moet Hennessy Louis...
NYSE
JPM
JP Morgan Chase
SPI
SP500
S&P 500
EU
RNO
Renault
EU
VIV
Vivendi
FTSE
UKX
FTSE 100
EU
GLE
Societe Generale
NYSE
DIS
Walt Disney
NASDAQ
AAPL
Apple
EU
EN
Bouygues
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés